UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2025
Commission File Number: 001-36515
Materialise NV
Technologielaan 15
3001 Leuven
Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
This Form 6-K is incorporated by reference into the registrant’s Registration Statement on Form F-3 (File No. 333-213649).
First Quarter 2025 Financial Results
Except as otherwise required by the context, references to “Materialise,” “Company,” “we,” “us” and “our” are to Materialise NV and its subsidiaries.
First Quarter 2025 Financial Results
Total revenue for the first quarter of 2025 increased 4.3% to 66,379 kEUR from 63,637 kEUR for the first quarter of 2024. Adjusted EBIT for the first quarter of 2025 was 646 kEUR compared to 2,656 kEUR for the 2024 period.
Revenue from our Materialise Medical segment increased 18.7% to 31,078 kEUR for the first quarter of 2025 compared to 26,183 kEUR for the same period in 2024.
Revenue from our Materialise Software segment decreased 6.4% to 9,775 kEUR for the first quarter of 2025 from 10,438 kEUR for the same quarter last year.
Revenue from our Materialise Manufacturing segment decreased 5.5% to 25,526 kEUR for the first quarter of 2025 from 27,016 kEUR for the first quarter of 2024.
Gross profit increased 2.2% to 36,724 kEUR compared to 35,935 kEUR for the same period last year, while gross profit as a percentage of revenue was 55.3% compared to 56.5% for the first quarter of 2024.
Research and development (“R&D”), sales and marketing (“S&M”) and general and administrative (“G&A”) expenses increased, in the aggregate, 6.9% to 36,510 kEUR for the first quarter of 2025 from 34,138 kEUR for the first quarter of 2024.
Net other operating income was 360 kEUR compared to 789 kEUR for the first quarter of 2024.
Operating result amounted to 574 kEUR compared to 2,585 kEUR for the first quarter of 2024.
Net financial result was (875) kEUR, compared to 1,510 kEUR for the first quarter of 2024, reflecting unfavorable effects from exchange rate fluctuations.
The first quarter of 2025 contained net tax expenses of (234) kEUR, compared to net tax expenses of (510) kEUR in the first quarter of 2024.
As a result of the above, net loss for the first quarter of 2025 was (535) kEUR, compared to a net profit of 3,585 kEUR for the same period in 2024. Total comprehensive loss for the first quarter of 2025, which includes exchange differences on translation of foreign operations, was (30) kEUR compared to 3,312 kEUR for the 2024 period.
At March 31, 2025, we had cash and cash equivalents of 104,180 kEUR compared to 102,304 kEUR at December 31, 2024. Gross debt amounted to 36,444 kEUR, compared to 41,284 kEUR at December 31, 2024. As a result, our net cash position increased by 6,716 kEUR to 67,736 kEUR.
Cash flow from operating activities for the first quarter of 2025 was 9,713 kEUR, compared to 9,970 kEUR for the same period in 2024. Total cash out from capital expenditures for the first quarter of 2025 amounted to 1,832 kEUR, resulting in a positive free cash flow.
Net shareholders’ equity at March 31, 2025 was 248,703 kEUR compared to 248,492 kEUR at December 31, 2024.
The Adjusted EBIT margin (Adjusted EBIT divided by total revenue) for the first quarter of 2025 was 1.0%, compared to 4.2% for the first quarter of 2024. Adjusted EBITDA for the first quarter of 2025 was 6,147 kEUR compared to 8,094 kEUR for the 2024 period.
Adjusted EBITDA from our Materialise Medical segment increased 14.2% to 9,047 kEUR for the first quarter of 2025 compared to 7,921 kEUR, while the segment Adjusted EBITDA margin (segment Adjusted EBITDA divided by segment revenue) was 29.1% compared to 30.3% for the first quarter of 2024.
Adjusted EBITDA from our Materialise Software segment decreased 45.1% to 599 kEUR from 1,090 kEUR, while the segment Adjusted EBITDA margin was 6.1%, compared to 10.4% for the prior-year period.
Adjusted EBITDA from our Materialise Manufacturing segment decreased to (377) kEUR from 1,529 kEUR, while the segment Adjusted EBITDA margin was (1.5)%, compared to 5.7% for the first quarter of 2024.
Non-IFRS Measures
Materialise uses EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA as supplemental financial measures of its financial performance. EBIT is calculated as net profit plus income taxes, financial expenses (less financial income) and shares of profit or loss in a joint venture. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of profit or loss in a joint venture and depreciation and amortization. Adjusted EBIT and Adjusted EBITDA are determined by adding share-based compensation expenses, acquisition-related expenses of business combinations, impairments and revaluation of fair value due to business combinations to EBIT and EBITDA, respectively. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of financing decisions and, in the case of EBITDA and Adjusted EBITDA, long term investment, rather than the performance of the company’s day-to-day operations. The company also uses segment Adjusted EBITDA to evaluate the performance of its three business segments. As compared to net profit, these measures are limited in that they do not reflect the cash requirements necessary to service interest or principal payments on the company’s indebtedness and, in the case of EBITDA and Adjusted EBITDA, these measures are further limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the company’s business, or the changes associated with impairments. Management evaluates such items through other financial measures such as financial expenses, capital expenditures and cash flow provided by operating activities. The company believes that these measurements are useful to measure a company’s ability to grow or as a valuation measurement. The company’s calculation of EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA should not be considered as alternatives to net profit or any other performance measure derived in accordance with IFRS. The company’s presentation of EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items.
Exchange Rate
This document contains translations of certain euro amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from euros to U.S. dollars in this document were made at a rate of EUR 1.00 to USD 1.0815, the reference rate of the European Central Bank on March 31, 2025.
About Materialise
Materialise incorporates over 30 years of 3D printing experience into a range of software solutions and 3D printing services, which form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines one of the largest groups of software developers in the industry with one of the largest and most complete 3D printing facilities in the world.
Consolidated income statements (Unaudited)
| for the three months ended March 31, | ||||||||||||
| In '000 | 2025 | 2025 | 2024 | |||||||||
| U.S.$ | € | € | ||||||||||
| Revenue | 71,789 | 66,379 | 63,637 | |||||||||
| Cost of Sales | (32,071 | ) | (29,654 | ) | (27,702 | ) | ||||||
| Gross Profit | 39,717 | 36,724 | 35,935 | |||||||||
| Gross profit as % of revenue | 55.3 | % | 55.3 | % | 56.5 | % | ||||||
| Research and development expenses | (12,345 | ) | (11,414 | ) | (10,231 | ) | ||||||
| Sales and marketing expenses | (16,299 | ) | (15,071 | ) | (14,598 | ) | ||||||
| General and administrative expenses | (10,842 | ) | (10,025 | ) | (9,309 | ) | ||||||
| Net other operating income (expenses) | 389 | 360 | 789 | |||||||||
| Operating (loss) profit | 620 | 574 | 2,585 | |||||||||
| Financial expenses | (2,998 | ) | (2,772 | ) | (798 | ) | ||||||
| Financial income | 2,052 | 1,897 | 2,308 | |||||||||
| (Loss) profit before taxes | (326 | ) | (301 | ) | 4,096 | |||||||
| Income Taxes | (253 | ) | (234 | ) | (510 | ) | ||||||
| Net (loss) profit for the period | (579 | ) | (535 | ) | 3,585 | |||||||
| Net (loss) profit attributable to: | ||||||||||||
| The owners of the parent | (577 | ) | (533 | ) | 3,591 | |||||||
| Non-controlling interest | (2 | ) | (2 | ) | (6 | ) | ||||||
| Earning per share attributable to owners of the parent | ||||||||||||
| Basic | (0.01 | ) | (0.01 | ) | 0.06 | |||||||
| Diluted | (0.01 | ) | (0.01 | ) | 0.06 | |||||||
| Weighted average basic shares outstanding | 59,067 | 59,067 | 59,067 | |||||||||
| Weighted average diluted shares outstanding | 59,067 | 59,067 | 59,088 | |||||||||
Consolidated statements of comprehensive income (Unaudited)
| for the three months ended March 31, | ||||||||||||
| In 000€ | 2025 | 2025 | 2024 | |||||||||
| U.S.$ | € | € | ||||||||||
| Net profit (loss) for the period | (579 | ) | (535 | ) | 3,585 | |||||||
| Other comprehensive income | ||||||||||||
| Recycling | ||||||||||||
| Exchange difference on translation of foreign operations | 546 | 505 | (273 | ) | ||||||||
| Other comprehensive income (loss), net of taxes | 546 | 505 | (273 | ) | ||||||||
| Total comprehensive income (loss) for the year, net of taxes | (33 | ) | (30 | ) | 3,312 | |||||||
| Total comprehensive income (loss) attributable to: | ||||||||||||
| The owners of the parent | (34 | ) | (32 | ) | 3,319 | |||||||
| Non-controlling interests | 2 | 1 | (6 | ) | ||||||||
Consolidated statement of financial position (Unaudited)
| As of March 31, | As of December 31, | |||||||
| In 000€ | 2025 | 2024 | ||||||
| Assets | ||||||||
| Non-current assets | ||||||||
| Goodwill | 43,372 | 43,391 | ||||||
| Intangible assets | 28,772 | 29,973 | ||||||
| Property, plant & equipment | 110,906 | 111,331 | ||||||
| Right-of-Use assets | 7,337 | 7,719 | ||||||
| Deferred tax assets | 3,407 | 3,523 | ||||||
| Investments in convertible loans | 4,055 | 3,994 | ||||||
| Other non-current assets | 6,274 | 5,893 | ||||||
| Total non-current assets | 204,123 | 205,823 | ||||||
| Current assets | ||||||||
| Inventories | 16,148 | 16,992 | ||||||
| Trade receivables | 49,571 | 53,052 | ||||||
| Other current assets | 16,432 | 18,166 | ||||||
| Cash and cash equivalents | 104,180 | 102,304 | ||||||
| Total current assets | 186,331 | 190,513 | ||||||
| Total assets | 390,454 | 396,336 | ||||||
| As of March 31, | As of December 31, | |||||||
| In 000€ | 2025 | 2024 | ||||||
| Equity and liabilities | ||||||||
| Equity | ||||||||
| Share capital | 4,487 | 4,487 | ||||||
| Share premium | 233,895 | 233,895 | ||||||
| Retained earnings and other reserves | 10,405 | 10,197 | ||||||
| Equity attributable to the owners of the parent | 248,787 | 248,578 | ||||||
| Non-controlling interest | (84 | ) | (86 | ) | ||||
| Total equity | 248,703 | 248,492 | ||||||
| Non-current liabilities | ||||||||
| Loans & borrowings | 19,450 | 23,175 | ||||||
| Lease liabilities | 4,970 | 5,112 | ||||||
| Deferred tax liabilities | 2,982 | 3,202 | ||||||
| Deferred income | 14,653 | 13,268 | ||||||
| Other non-current liabilities | 832 | 910 | ||||||
| Total non-current liabilities | 42,887 | 45,666 | ||||||
| Current liabilities | ||||||||
| Loans & borrowings | 9,502 | 10,383 | ||||||
| Lease liabilities | 2,522 | 2,614 | ||||||
| Trade payables | 21,303 | 23,348 | ||||||
| Tax payables | 787 | 1,432 | ||||||
| Deferred income | 46,435 | 45,998 | ||||||
| Other current liabilities | 18,315 | 18,403 | ||||||
| Total current liabilities | 98,864 | 102,178 | ||||||
| Total equity and liabilities | 390,454 | 396,336 | ||||||
Consolidated statement of cash flows (Unaudited)
| for the three months ended March 31, | ||||||||
| In 000€ | 2025 | 2024 | ||||||
| Operating activities | ||||||||
| Net (loss) profit for the period | (535 | ) | 3,585 | |||||
| Non-cash and operational adjustments | 6,994 | 4,637 | ||||||
| Depreciation of property plant & equipment | 3,854 | 3,765 | ||||||
| Amortization of intangible assets | 1,631 | 1,672 | ||||||
| Share-based payment expense | 72 | 71 | ||||||
| Loss (gain) on disposal of intangible assets and property, plant & equipment | 21 | (132 | ) | |||||
| Movement in provisions | 18 | 79 | ||||||
| Movement reserve for bad debt and slow moving inventory | 243 | 188 | ||||||
| Financial income | (1,834 | ) | (2,309 | ) | ||||
| Financial expense | 2,763 | 797 | ||||||
| Impact of foreign currencies | (2 | ) | (5 | ) | ||||
| (Deferred) income taxes | 228 | 510 | ||||||
| Working capital adjustments | 3,763 | 1,029 | ||||||
| Decrease (increase) in trade receivables and other receivables | 4,487 | 3,712 | ||||||
| Decrease (increase) in inventories and contracts in progress | 948 | (10 | ) | |||||
| Increase (decrease) in deferred revenue | 1,868 | 643 | ||||||
| Increase (decrease) in trade payables and other payables | (3,539 | ) | (3,315 | ) | ||||
| Income tax paid & Interest received | (509 | ) | 718 | |||||
| Net cash flow from operating activities | 9,713 | 9,970 | ||||||
| for the three months ended March 31, | ||||||||
| In 000€ | 2025 | 2024 | ||||||
| Investing activities | ||||||||
| Purchase of property, plant & equipment | (1,400 | ) | (2,525 | ) | ||||
| Purchase of intangible assets | (432 | ) | (306 | ) | ||||
| Proceeds from the sale of property, plant & equipment & intangible assets (net) | 75 | 206 | ||||||
| Net cash flow used in investing activities | (1,757 | ) | (2,624 | ) | ||||
| Financing activities | ||||||||
| Repayment of loans & borrowings | (4,472 | ) | (4,876 | ) | ||||
| Repayment of leases | (815 | ) | (757 | ) | ||||
| Capital increase | - | - | ||||||
| Interest paid | (235 | ) | (358 | ) | ||||
| Other financial income (expense) | (310 | ) | (5 | ) | ||||
| Net cash flow from (used in) financing activities | (5,832 | ) | (5,997 | ) | ||||
| Net increase/(decrease) of cash & cash equivalents | 2,123 | 1,348 | ||||||
| Cash & Cash equivalents at the beginning of the year | 102,304 | 127,573 | ||||||
| Exchange rate differences on cash & cash equivalents | (247 | ) | (22 | ) | ||||
| Cash & cash equivalents at end of the period | 104,180 | 128,899 | ||||||
Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited)
| for the three months ended March 31, | ||||||||
| In 000€ | 2025 | 2024 | ||||||
| Net profit (loss) for the period | (535 | ) | 3,585 | |||||
| Income taxes | 234 | 510 | ||||||
| Financial expenses | 2,772 | 798 | ||||||
| Financial income | (1,897 | ) | (2,308 | ) | ||||
| Depreciation and amortization | 5,501 | 5,438 | ||||||
| EBITDA | 6,075 | 8,023 | ||||||
| Share-based compensation expense (1) | 72 | 71 | ||||||
| Adjusted EBITDA | 6,147 | 8,094 | ||||||
(1) Share-based compensation expense represents the cost of equity-settled and share-based payments to employees.
Reconciliation of Net Profit (Loss) to EBIT and Adjusted EBIT (Unaudited)
| for the three months ended March 31, | ||||||||
| In 000€ | 2025 | 2024 | ||||||
| Net profit (loss) for the period | (535 | ) | 3,585 | |||||
| Income taxes | 234 | 510 | ||||||
| Financial expenses | 2,772 | 798 | ||||||
| Financial income | (1,897 | ) | (2,308 | ) | ||||
| EBIT | 574 | 2,585 | ||||||
| Share-based compensation expense (1) | 72 | 71 | ||||||
| Adjusted EBIT | 646 | 2,656 | ||||||
(1) Share-based compensation expense represents the cost of equity-settled and share-based payments to employees.
Segment P&L (Unaudited)
| In 000€ | Materialise Medical | Materialise Software | Materialise Manufacturing | Total segments | Unallocated (1) | Consolidated | ||||||||||||||||||
| For the three months ended March 31, 2025 | ||||||||||||||||||||||||
| Revenues | 31,078 | 9,775 | 25,526 | 66,379 | 0 | 66,379 | ||||||||||||||||||
| Segment (adj) EBITDA | 9,047 | 599 | (377 | ) | 9,269 | (3,122 | ) | 6,147 | ||||||||||||||||
| Segment (adj) EBITDA % | 29.1 | % | 6.1 | % | -1.5 | % | 14.0 | % | 9.3 | % | ||||||||||||||
| For the three months ended March 31, 2024 | ||||||||||||||||||||||||
| Revenues | 26,183 | 10,438 | 27,016 | 63,637 | 0 | 63,637 | ||||||||||||||||||
| Segment (adj) EBITDA | 7,921 | 1,090 | 1,529 | 10,540 | (2,446 | ) | 8,094 | |||||||||||||||||
| Segment (adj) EBITDA % | 30.3 | % | 10.4 | % | 5.7 | % | 16.6 | % | 12.7 | % | ||||||||||||||
(1) Unallocated segment adjusted EBITDA consists of corporate research and development and corporate other operating income (expense), and the added share-based compensation expenses that are included in Adjusted EBITDA.
Reconciliation of Net Profit (Loss) to Segment adjusted EBITDA (Unaudited)
| for the three months ended March 31, | ||||||||
| In 000€ | 2025 | 2024 | ||||||
| Net profit (loss) for the period | (535 | ) | 3,585 | |||||
| Income taxes | 234 | 510 | ||||||
| Financial cost | 2,772 | 798 | ||||||
| Financial income | (1,897 | ) | (2,308 | ) | ||||
| Operating (loss) profit | 574 | 2,585 | ||||||
| Depreciation and amortization | 5,501 | 5,438 | ||||||
| Corporate research and development | 1,030 | 808 | ||||||
| Corporate headquarter costs | 2,852 | 2,484 | ||||||
| Other operating income (expense) | (688 | ) | (776 | ) | ||||
| Segment adjusted EBITDA | 9,269 | 10,540 | ||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MATERIALISE NV | ||
| By: |
/s/ Brigitte de Vet-Veithen | |
| Name: | Brigitte de Vet-Veithen | |
| De Vet Management BV | ||
| Title: | Chief Executive Officer | |
Date: April 24, 2025